Health-related quality of life in systemic sclerosis as measured by the short form 36: Relationship with clinical and biologic markers

Arthritis Care and Research

Volumn 51, Issue 3, 2004, Pages 475-481

  Del Rosso, Angela ^a   Boldrini, Maura ^a   D'Agostino, David ^a   Placidi, Giovanni Plinio Augusto ^a   Scarpato, Alessandra ^a   Pignone, Alberto ^a   Generini, Sergio ^a   Konttinen, Yrio ^b   Zoppi, Massimo ^a   Vlak, Tonko ^c   Placidi, Gianfranco ^a   Matucci Cerinic, Marco ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF SPLIT   (Croatia)

Author keywords

Coping; Health related quality of life; SF 36; Systemic sclerosis

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FUNCTIONAL ASSESSMENT; HEALTH STATUS; HEALTH SURVEY; HUMAN; LABORATORY TEST; MALE; MEASUREMENT; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SHORT FORM 36; SYSTEMIC SCLEROSIS;

EID: 2642556433     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20389     Document Type: Article

References (33)

1. Clements PJ, Furst DE. Systemic sclerosis. Baltimore: Williams & Wilkins; 1995.
2. Poole JL, Steen VD. The use of Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis. Arthritis Care Res 1991;4:27-31.
3. Steen VD, Medsger TA jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patient over time. Arthritis Rheum 1997;40:1984-91.
4. Silman A, Akesson A, Newman J, Henriksson H, Sandquist G, Nihill M, et al. Assessment of functional ability in patients with scleroderma: a proposed new disability assessment instrument. J Rheumatol 1998;25:79-83.
5. Ruof J, Bruhlmann P, Stucki. Development and validation of a self-administered Systemic Sclerosis Questionnaire (SySQ). Rheumatology 1999;38:535-42.
6. Stewart AL, Greenfield S, Hays RD, Wells KB, Rogers WH, Berry SD, et al. Functional status and well-being of patients with chronic condition: results from the Medical Outcomes Study. JAMA 1989;262:907-13.
7. Stewart AL, Hays RD, Ware JE Jr. The MOS short-form general health survey: reliability and validity in a patients population. Med Care 1988;26:724-35.
8. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
9. Nilsdotter AK, Roos EM, Westerlund JP, Roos HP, Lohmander LS. Comparative responsiveness of measures of pain and function after total hip replacement. Arthritis Rheum 2001; 45:258-62.
10. Goorman SD, Watanabe TK, Miller EH, Perry C. Functional outcome in knee osteoarthritis after treatment with hylan G-F 20: a prospective study. Arch Phys Med Rehabil 2000;81:479-83.
11. Birrell FN, Hassell AB, Jones PW, Dawes PT. How does the short form 36 health questionnaire (SF-36) in rheumatoid arthritis (RA) relate to RA outcome measures and SF-36 population values: a cross-sectional study. Clin Rheumatol 2000; 19:195-9.
12. Tugwell P, Wells G, Strand V, Maetzel A, Bombardier C, Crawford B, et al, Leflunomide Rheumatoid Arthritis Investigators Group. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Arthritis Rheum 2000;43:506-14.
13. Thomas E, Hay EM, Hajeer A, Silman AJ. Sjogren's syndrome: a community-based study of prevalence and impact. Br J Rheumatol 1998;37:1069-76.
14. Strombeck B, Ekdahl C, Manthorpe R, Wikstrom I, Jacobsson L. Health-related quality of life in primary Sjogren's syndrome, rheumatoid arthritis and fibromyalgia compared to normal population data using SF 36. Scand J Rheumatol 2000; 29:20-8.
15. Friedman AW, Alarcon GS, McGwin G Jr, Straaton KV, Roseman J, Goel N, et al, LUMINA Study Group: Lupus in Minority Populations, Nature versus Nurture. Systemic lupus erythematosus in three ethnic groups. IV. Factors associated with self-reported functional outcome in a large cohort study. Arthritis Care Res 1999;12:256-66.
16. Stoll T, Gordon C, Seifert B, Richardson K, Malik J, Bacon PA, et al. Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus. J Rheumatol 1997;24:1608-14.
17. Da Costa D, Dobkin PL, Fitzcharles MA, Fortin PR, Beaulieu A, Zummer M, et al. Determinants of health status in fibromyalgia: a comparative study with systemic lupus erythematosus. J Rheumatol 2000;27:365-72.
18. LeRoy EC, Black C, Fleishmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (SSc): classification, subsets, and pathogenesis. J Rheumatol 1998;15:201-5.
19. Apoloni G, Mosconi P, Ware JE Jr. Questionario sullo stato di salute SF 36: Manuale d'uso e guida all'interpretazione dei risultati. Milano: Guerini e Associati; 1997.
20. Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
21. , Wells AU, Hansell DM, Corrin B, Harrison NK, Goldstraw P, Black CM, et al. High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax 1992; 47:738-42.
22. Matucci Cerinic M, Jaffa A, Kahaleh BM. Angiotensin converting enzyme: an in vivo and in vitro marker of endothelial injury. J Lab Clin Med 1992;120:428-33.
23. Pignone A, Generini S, Matucci Cerinic M. Prostaglandin El restores the levels of vWF and ACE in chronic critical limb ischemia in systemic sclerosis. Clin Exp Rheumatol 2001;19: 358-9.
24. Lori S, Matucci Cerinic M, Casale R, Generini S, Lombardi A, Pignone A, et al. Peripheral neuropathy in systemic sclerosis: the median nerve as a target structure. Clin Exp Rheumatol 1996;14:601-5.
25. Pignone A, Scaletti C, Matucci Cerinic M, Vazquez-Abad D, Del Papa N, Meroni PL, et al. Antiendothelial cell antibodies in systemic sclerosis: correlation with vascular involvement. Clin Exp Rheumatol 1998;16:572-7.
26. Clark PE, Schover LR, Uzzo RG, Hafez KS, Rybicki LA, Novick AC. Quality of life and psychological adaptation after surgical treatment for localized renal cell carcinoma: impact of the amount of remaining renal tissue. Urology 2001;57:252-6.
27. Janda M, Gerstner N, Obermair A, Fuerst A, Wachter S, Dieckmann K, et al. Quality of life changes during conformal radiation therapy for prostate carcinoma. Cancer 2000;89:1322-8.
28. Forjaz MJ, Guarnaccia CA. Hematological cancer patients' quality of life: self versus intimate or non-intimate confidant reports. Psychooncology 1999;8:546-52.
29. Angermann CE, Bullinger M, Spes CH, Zellner M, Kemkes BM, Theisen K. Quality of life in long-term survivors of orthotopic heart transplantation. Z Kardiol 1992;81:411-7.
30. Stull DE, Starling R, Haas G, Young JB. Becoming a patient with heart failure. Heart Lung 1999;28:284-92.
31. Moser DK, Clements PJ, Brecht ML, Weiner SR. Predictors of psychosocial adjustment in systemic sclerosis: the influence of formal education level, functional ability, hardiness, uncertainty, and social support. Arthritis Rheum 1993;36:1398-405.
32. Roca RP, Wigley FM, White B. Depressive symptoms associated with scleroderma. Arthritis Rheum 1996;39:1035-40.
33. Angelopoulos NV, Drosos AA, Moutsopoulos HM. Psychiatric symptoms associated with scleroderma. Psychother Psychosom 2001;70:145-50.